StockData

Novavax Inc (NVAX) bonds

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.96−0.10 (-1.24%)

Close on Nov 17, 2026Market cap $1.31BP/E –Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Novavax reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Notes and loans outstanding

As tagged in Novavax's 10-Q for the period ended Jun 30, 2026

IssueMaturesAmount issuedCarrying value
5.00% Convertible Senior Notes due 2027
Convertible
2027$26.49M$26.49M
5.00% Convertible notes due 2027
Convertible at $13 a share
2027$175.30M–
4.625% Convertible Senior Notes due 2031
Convertible at $11 a share
2031$225.00M$225.00M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeDrawn
Credit Agreement due 2031$330.00M$50.00M

See a number that looks wrong?